These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 11196267)

  • 1. Prospective randomized trial between two doses of granulocyte colony-stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent or refractory solid tumors: a children's cancer group report.
    Cairo MS; Shen V; Krailo MD; Bauer M; Miser JS; Sato JK; Blatt J; Blazar BR; Frierdich S; Liu-Mares W; Reaman GH
    J Pediatr Hematol Oncol; 2001 Jan; 23(1):30-8. PubMed ID: 11196267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Phase I study of granulocyte-macrophage-colony stimulating factor/interleukin-3 fusion protein (PIXY321) following ifosfamide, carboplatin, and etoposide therapy for children with recurrent or refractory solid tumors: a report of the Children's Cancer Group.
    Cairo MS; Krailo MD; Weinthal JA; Secola R; Bergeron S; van de Ven C; Blazar BR; Garrison L; Reaman GH
    Cancer; 1998 Oct; 83(7):1449-60. PubMed ID: 9762948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I clinical, pharmacological, and biological trial of interleukin 6 plus granulocyte-colony stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent/refractory solid tumors: enhanced hematological responses but a high incidence of grade III/IV constitutional toxicities.
    Bracho F; Krailo MD; Shen V; Bergeron S; Davenport V; Liu-Mares W; Blazar BR; Panoskaltsis-Mortari A; van de Ven C; Secola R; Ames MM; Reid JM; Reaman GH; Cairo MS
    Clin Cancer Res; 2001 Jan; 7(1):58-67. PubMed ID: 11205919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Failure of granulocyte-macrophage colony-stimulating factor to reduce febrile neutropenia in children with recurrent solid tumors treated with ifosfamide, carboplatin, and etoposide chemotherapy.
    Marina NM; Shema SJ; Bowman LC; Rodman J; Douglass EC; Furman WL; Pappo A; Santana VM; Hudson M; Meyer WH
    Med Pediatr Oncol; 1994; 23(4):328-34. PubMed ID: 8058003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I clinical, pharmacologic, and biologic study of thrombopoietin and granulocyte colony-stimulating factor in children receiving ifosfamide, carboplatin, and etoposide chemotherapy for recurrent or refractory solid tumors: a Children's Oncology Group experience.
    Angiolillo AL; Davenport V; Bonilla MA; van de Ven C; Ayello J; Militano O; Miller LL; Krailo M; Reaman G; Cairo MS;
    Clin Cancer Res; 2005 Apr; 11(7):2644-50. PubMed ID: 15814645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of hematopoietic growth factors in support of ifosfamide/carboplatin/etoposide chemotherapy.
    Crawford J; George M
    Semin Oncol; 1995 Jun; 22(3 Suppl 7):18-22. PubMed ID: 7541916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ifosfamide, carboplatin, and etoposide plus granulocyte-macrophage colony-stimulating factor: a phase I study with apparent activity in non-small-cell lung cancer.
    Krigel RL; Palackdharry CS; Padavic K; Haas N; Kilpatrick D; Langer C; Comis R
    J Clin Oncol; 1994 Jun; 12(6):1251-8. PubMed ID: 8201386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcome of pediatric recurrent and refractory malignant solid tumors following ifosfamide/carboplatin/etoposide (ICE): A phase II study in a pediatric oncology centre in Brazil.
    Loss JF; Santos PP; Leone LD; Brunetto AL
    Pediatr Blood Cancer; 2004 Feb; 42(2):139-44. PubMed ID: 14752877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ifosfamide, carboplatin, and etoposide (ICE) reinduction chemotherapy in a large cohort of children and adolescents with recurrent/refractory sarcoma: the Children's Cancer Group (CCG) experience.
    Van Winkle P; Angiolillo A; Krailo M; Cheung YK; Anderson B; Davenport V; Reaman G; Cairo MS
    Pediatr Blood Cancer; 2005 Apr; 44(4):338-47. PubMed ID: 15503297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized phase II study of ifosfamide/mesna/cisplatin plus G-CSF or etoposide/cisplatin plus G-CSF in advanced non-small cell lung cancer: a Cancer and Leukemia Group B study.
    Graziano SL; Valone FH; Herndon JE; Crawford J; Richards F; Rege VB; Clamon G; Green MR
    Lung Cancer; 1996 Jun; 14(2-3):315-29. PubMed ID: 8794413
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ifosfamide, carboplatin, etoposide, and paclitaxel chemotherapy: a dose-escalation study.
    Chang AY; Boros L; Garrow GC; Asbury RF; Hui L
    Semin Oncol; 1996 Jun; 23(3 Suppl 6):74-7. PubMed ID: 8677454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized trial of filgrastim vs. sequential filgrastim and molgramostim after dose-intensified carboplatin, cyclophosphamide, and etoposide: a phase I pilot study.
    Recchia F; De Filippis S; Torchio P; Rea S; Gulino A; Quaglino D; Frati L
    Am J Clin Oncol; 1997 Apr; 20(2):209-14. PubMed ID: 9124202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Feasibility study of IL-11 and granulocyte colony-stimulating factor after myelosuppressive chemotherapy to mobilize peripheral blood stem cells from heavily pretreated patients.
    Goldman SC; Bracho F; Davenport V; Slack R; Areman E; Shen V; Lenarsky C; Weinthal J; Hughes R; Cairo MS
    J Pediatr Hematol Oncol; 2001; 23(5):300-5. PubMed ID: 11464987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can cytotoxic dose-intensity be increased by using granulocyte colony-stimulating factor? A randomized controlled trial of lenograstim in small-cell lung cancer.
    Woll PJ; Hodgetts J; Lomax L; Bildet F; Cour-Chabernaud V; Thatcher N
    J Clin Oncol; 1995 Mar; 13(3):652-9. PubMed ID: 7533825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peripheral blood progenitor cells mobilized by chemotherapy plus granulocyte-colony stimulating factor accelerate both neutrophil and platelet recovery after high-dose VP16, ifosfamide and cisplatin.
    Brugger W; Birken R; Bertz H; Hecht T; Pressler K; Frisch J; Schulz G; Mertelsmann R; Kanz L
    Br J Haematol; 1993 Jul; 84(3):402-7. PubMed ID: 7692928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of recombinant human granulocyte colony-stimulating factor to increase chemotherapy dose-intensity: a randomized trial in very high-risk childhood acute lymphoblastic leukemia.
    Michel G; Landman-Parker J; Auclerc MF; Mathey C; Leblanc T; Legall E; Bordigoni P; Lamagnere JP; Demeocq F; Perel Y; Auvrignon A; Berthou C; Bauduer F; Pautard B; Schneider P; Schaison G; Leverger G; Baruchel A
    J Clin Oncol; 2000 Apr; 18(7):1517-24. PubMed ID: 10735900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized phase-III study of the efficacy of granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia. Berlin-Frankfurt-Münster Study Group.
    Welte K; Reiter A; Mempel K; Pfetsch M; Schwab G; Schrappe M; Riehm H
    Blood; 1996 Apr; 87(8):3143-50. PubMed ID: 8605328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in treatment of newly diagnosed pediatric solid tumors.
    Marina NM; Rodman JH; Murry DJ; Shema SJ; Bowman LC; Jones DP; Furman W; Meyer WH; Pratt CB
    J Natl Cancer Inst; 1994 Apr; 86(7):544-8. PubMed ID: 8133538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Etoposide, ifosfamide, and cisplatin therapy for refractory childhood solid tumors. Response and toxicity.
    van Hoff J; Grier HE; Douglass EC; Green DM
    Cancer; 1995 Jun; 75(12):2966-70. PubMed ID: 7773949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outpatient-based ifosfamide, carboplatin and etoposide (ICE) chemotherapy in transplant-eligible patients with non-Hodgkin's lymphoma and Hodgkin's disease.
    Hertzberg MS; Crombie C; Benson W; Taper J; Gottlieb D; Bradstock KF
    Ann Oncol; 2003; 14 Suppl 1():i11-6. PubMed ID: 12736225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.